Synvisc-One approved for osteoarthritis knee

Synvisc-One (hylan G-F 20, from Genzyme), has been FDA approved for the relief of pain associated with osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.  Synvisc-One is given as a single-injection viscosupplement that is administered through an intra-articular injection. It is an alternative treatment regimen to Genzyme's Synvisc (hylan G-F 20), a three-injection viscosupplement.

For more information call (800) 745-4447 or visit www.synvisc.com.